Tumor-infiltrating immune cells as potential biomarkers predicting response to treatment and survival in patients with metastatic melanoma receiving ipilimumab therapy
暂无分享,去创建一个
Judit Oláh | Z. Lengyel | G. Emri | G. Liszkay | A. Ladányi | Gabriella Liszkay | Tímea Balatoni | Anita Mohos | Eszter Papp | Tímea Sebestyén | Anita Varga | Zsuzsanna Lengyel | Gabriella Emri | István Gaudi | Andrea Ladányi | T. Balatoni | J. Oláh | A. Varga | I. Gaudi | E. Papp | Anita Mohos | T. Sebestyén
[1] G. Dranoff,et al. Activating Fc γ receptors contribute to the antitumor activities of immunoregulatory receptor-targeting antibodies , 2013, The Journal of experimental medicine.
[2] Yan Zheng,et al. Cancer immunotherapy strategies based on overcoming barriers within the tumor microenvironment. , 2013, Current opinion in immunology.
[3] D. Jukic. T-Cell Activation Marker Expression on Tumor-infiltrating Lymphocytes as Prognostic Factor in Cutaneous Malignant Melanoma , 2006 .
[4] A. Korman,et al. Anti-CTLA-4 Antibodies of IgG2a Isotype Enhance Antitumor Activity through Reduction of Intratumoral Regulatory T Cells , 2013, Cancer Immunology Research.
[5] Jason B. Williams,et al. Up-Regulation of PD-L1, IDO, and Tregs in the Melanoma Tumor Microenvironment Is Driven by CD8+ T Cells , 2013, Science Translational Medicine.
[6] Paolo A Ascierto,et al. Biomarkers for Immunostimulatory Monoclonal Antibodies in Combination Strategies for Melanoma and Other Tumor Types , 2013, Clinical Cancer Research.
[7] G. Liszkay,et al. 524 Tumor-infiltrating immune cells as potential biomarkers predicting response to treatment and survival in patients with metastatic melanoma receiving ipilimumab therapy , 2015 .
[8] L. Zitvogel,et al. Immunologic correlates in the course of treatment with immunomodulating antibodies. , 2015, Seminars in oncology.
[9] Henrik Schmidt,et al. A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma , 2011, Journal of Translational Medicine.
[10] Rui-Ru Ji,et al. An immune-active tumor microenvironment favors clinical response to ipilimumab , 2012, Cancer Immunology, Immunotherapy.
[11] R. Emerson,et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance , 2014, Nature.
[12] D. Schadendorf,et al. Improved survival with ipilimumab in patients with metastatic melanoma. , 2010, The New England journal of medicine.
[13] C. Slingluff,et al. Immunotype and immunohistologic characteristics of tumor-infiltrating immune cells are associated with clinical outcome in metastatic melanoma. , 2012, Cancer research.
[14] A. Enk,et al. Therapeutic use of anti-CTLA-4 antibodies. , 2015, International immunology.
[15] J. Wolchok,et al. Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti–CTLA-4 therapy against melanoma , 2013, The Journal of experimental medicine.
[16] J. Weber,et al. Exposure–Response Relationships of the Efficacy and Safety of Ipilimumab in Patients with Advanced Melanoma , 2013, Clinical Cancer Research.
[17] D. Schadendorf,et al. Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] Keunchil Park,et al. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial , 2016, The Lancet.
[19] J. Tímár,et al. FOXP3+ Cell Density in Primary Tumor Has No Prognostic Impact in Patients with Cutaneous Malignant Melanoma , 2010, Pathology & Oncology Research.
[20] Axel Hoos,et al. Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria , 2009, Clinical Cancer Research.
[21] D. Schadendorf,et al. Baseline Peripheral Blood Biomarkers Associated with Clinical Outcome of Advanced Melanoma Patients Treated with Ipilimumab , 2016, Clinical Cancer Research.
[22] J. Wolchok,et al. Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma. , 2015, The New England journal of medicine.
[23] H. Kohrt,et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients , 2014, Nature.
[24] A. Ribas,et al. CTLA4 Blockade Induces Frequent Tumor Infiltration by Activated Lymphocytes Regardless of Clinical Responses in Humans , 2011, Clinical Cancer Research.
[25] J. Tímár,et al. Prognostic impact of B-cell density in cutaneous melanoma , 2011, Cancer Immunology, Immunotherapy.
[26] J. Taube,et al. Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti–PD-1 Therapy , 2014, Clinical Cancer Research.
[27] M. Postow,et al. Emerging Tissue and Blood-Based Biomarkers that may Predict Response to Immune Checkpoint Inhibition , 2016, Current Oncology Reports.
[28] C. Meyer,et al. Ipilimumab-dependent cell-mediated cytotoxicity of regulatory T cells ex vivo by nonclassical monocytes in melanoma patients , 2015, Proceedings of the National Academy of Sciences.
[29] J. Wolchok,et al. Integrated NY-ESO-1 antibody and CD8+ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab , 2011, Proceedings of the National Academy of Sciences.
[30] Axel Hoos,et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. , 2011, The New England journal of medicine.
[31] Drew M. Pardoll,et al. The blockade of immune checkpoints in cancer immunotherapy , 2012, Nature Reviews Cancer.